Inmune Bio Inc.
INMB· Nasdaq
Released Aug 3, 2022, after the close
10-Q filed Aug 3, 2022, 34 days after period end · 0001213900-22-044453
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $16.00K | $0.00 | — | $0.00 |
| Net Income | -$6.84M | -$6.66M | -$2.11M | -$392.08K |
| EPS Diluted |
Inmune Bio Inc. · CIK 1711754 · Engraved from SEC EDGAR
| -$0.38 |
| -$0.44 |
| -$0.20 |
| -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.